Total Payments
$28,345
2024 Payments
$1,082
Companies
5
Transactions
30
Medicare Patients
732
Medicare Billing
$115,982
Payment Breakdown by Category
Research$15,354 (54.2%)
Consulting$6,218 (21.9%)
Other$3,961 (14.0%)
Education$1,295 (4.6%)
Travel$1,099 (3.9%)
Food & Beverage$417.84 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,354 | 9 | 54.2% |
| Consulting Fee | $6,218 | 2 | 21.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,961 | 5 | 14.0% |
| Education | $1,295 | 1 | 4.6% |
| Travel and Lodging | $1,099 | 6 | 3.9% |
| Food and Beverage | $417.84 | 7 | 1.5% |
Payments by Type
Research
$15,354
9 transactions
General
$12,991
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aadi Bioscience, Inc. | $11,965 | 3 | $0 (2023) |
| F. Hoffmann-La Roche AG | $8,690 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,298 | 4 | $0 (2018) |
| Eisai Inc. | $3,189 | 4 | $0 (2017) |
| Genentech, Inc. | $1,204 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,082 | 2 | F. Hoffmann-La Roche AG ($1,082) |
| 2023 | $11,965 | 3 | Aadi Bioscience, Inc. ($11,965) |
| 2021 | $1,459 | 3 | F. Hoffmann-La Roche AG ($1,459) |
| 2020 | $2,188 | 3 | F. Hoffmann-La Roche AG ($2,188) |
| 2019 | $4,441 | 9 | F. Hoffmann-La Roche AG ($3,323) |
| 2018 | $3,936 | 5 | Novartis Pharmaceuticals Corporation ($3,298) |
| 2017 | $3,274 | 5 | Eisai Inc. ($3,189) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $365.91 | Research |
| Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $715.76 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 11/03/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Education | In-kind items and services | $1,295.00 | General |
| Category: Cancer | ||||||
| 11/03/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Travel and Lodging | In-kind items and services | $45.00 | General |
| Category: Cancer | ||||||
| 04/06/2023 | Aadi Bioscience, Inc. | FYARRO (Drug) | — | Cash or cash equivalent | $10,625.00 | Research |
| Study: A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. • Category: Oncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $749.32 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $566.81 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | Alecensa (Biological) | — | In-kind items and services | $143.00 | Research |
| Study: PHASE II STUDY OF TKIS AS NEOADJUVANT THERAPY IN STAGE II III RESECTABLE NSCLC WITH ALK, ROS1, NTRK OR BRAF V600 ALTERATIONS • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Alecensa (Biological) | — | In-kind items and services | $1,141.25 | Research |
| Study: Phase II Study of TKIs as Neoadjuvant Therapy in Stage I-III Resectable NSCLC with ALK, ROS1, NTRK, or BRAFV600 Alterations • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $569.74 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $477.06 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $714.78 | General |
| Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $583.20 | General |
| Category: BioOncology | ||||||
| 06/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $700.31 | General |
| Category: BioOncology | ||||||
| 06/04/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | Cash or cash equivalent | $543.60 | General |
| Category: None | ||||||
| 06/04/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | Cash or cash equivalent | $382.69 | General |
| Category: None | ||||||
| 06/04/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $74.04 | General |
| Category: None | ||||||
| 06/04/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: None | ||||||
| 06/04/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | Cash or cash equivalent | $48.11 | General |
| Category: None | ||||||
| 03/31/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,324.28 | General |
| Category: BioOncology | ||||||
| 06/30/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $638.60 | General |
| Category: BioOncology | ||||||
| 03/17/2018 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,125.00 | General |
| 03/17/2018 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $115.00 | General |
| 03/17/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $38.00 | General |
| 03/17/2018 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $19.75 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | Aadi Bioscience, Inc. | $10,625 | 1 |
| LCMC3 | F. Hoffmann-La Roche AG | $1,763 | 3 |
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $1,316 | 2 |
| Phase II Study of TKIs as Neoadjuvant Therapy in Stage I-III Resectable NSCLC with ALK, ROS1, NTRK, or BRAFV600 Alterations | F. Hoffmann-La Roche AG | $1,141 | 1 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
| PHASE II STUDY OF TKIS AS NEOADJUVANT THERAPY IN STAGE II III RESECTABLE NSCLC WITH ALK, ROS1, NTRK OR BRAF V600 ALTERATIONS | F. Hoffmann-La Roche AG | $143.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 189 | 357 | $183,715 | $33,368 |
| 2022 | 4 | 205 | 378 | $184,977 | $34,219 |
| 2021 | 5 | 192 | 359 | $125,933 | $29,410 |
| 2020 | 4 | 146 | 299 | $80,642 | $18,986 |
Total Patients
732
Total Services
1,393
Medicare Billing
$115,982
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 161 | $65,708 | $12,997 | 19.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 97 | $71,010 | $11,822 | 16.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 32 | 32 | $28,349 | $4,883 | 17.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 41 | 67 | $18,648 | $3,665 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 72 | 156 | $62,388 | $12,696 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 50 | 101 | $71,986 | $12,271 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 53 | 91 | $24,633 | $4,730 | 19.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 30 | 30 | $25,970 | $4,521 | 17.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 73 | 178 | $40,716 | $9,986 | 24.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 47 | 91 | $31,509 | $7,857 | 24.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 28 | 43 | $26,739 | $5,321 | 19.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 31 | 31 | $22,601 | $5,021 | 22.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 16 | $4,368 | $1,226 | 28.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 65 | 168 | $30,913 | $7,233 | 23.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 35 | 83 | $23,085 | $5,607 | 24.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $16,974 | $4,175 | 24.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 18 | 20 | $9,670 | $1,971 | 20.4% |
About Dr. David Kwiatkowski, MD
Dr. David Kwiatkowski, MD is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114010311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Kwiatkowski, MD has received a total of $28,345 in payments from pharmaceutical and medical device companies, with $1,082 received in 2024. These payments were reported across 30 transactions from 5 companies. The most common payment nature is "" ($15,354).
As a Medicare-enrolled provider, Kwiatkowski has provided services to 732 Medicare beneficiaries, totaling 1,393 services with total Medicare billing of $115,982. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Boston, MA
- Active Since 10/02/2006
- Last Updated 07/09/2007
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1114010311
Products in Payments
- FYARRO (Drug) $10,625
- TECENTRIQ (Biological) $5,277
- Tecentriq (Biological) $2,128
- Fyarro (Drug) $1,340
- Alecensa (Biological) $1,284
- Non-Covered Product (Drug) $1,118
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701